Truist Securities Initiates Coverage On Y-mAbs Therapeutics with Buy Rating, Announces Price Target of $21
Y-mAbs Therapeutics +2.28% Pre
Y-mAbs Therapeutics YMAB | 14.81 14.81 | +2.28% 0.00% Pre |
Truist Securities analyst Nicole Germino initiates coverage on Y-mAbs Therapeutics (NASDAQ:
YMAB) with a Buy rating and announces Price Target of $21.